Viewray Inc (NASDAQ:VRAY) was the target of unusually large options trading activity on Tuesday. Traders acquired 2,022 put options on the company. This is an increase of 1,188% compared to the typical daily volume of 157 put options.
Shares of Viewray (VRAY) opened at $10.12 on Friday. The stock has a market cap of $649.77, a price-to-earnings ratio of -9.28 and a beta of 17.60. Viewray has a fifty-two week low of $3.01 and a fifty-two week high of $10.64. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million for the quarter, compared to analysts’ expectations of $18.63 million. Viewray’s revenue was up 2950.0% compared to the same quarter last year. analysts anticipate that Viewray will post -0.93 EPS for the current fiscal year.
VRAY has been the topic of a number of research reports. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Mizuho reiterated a “buy” rating and issued a $12.00 price objective on shares of Viewray in a report on Tuesday, September 26th. Northland Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Viewray in a report on Friday, November 17th. BidaskClub cut shares of Viewray from a “buy” rating to a “hold” rating in a report on Saturday, December 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Viewray in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Viewray currently has an average rating of “Buy” and a consensus price target of $11.20.
Large investors have recently modified their holdings of the stock. Nationwide Fund Advisors boosted its holdings in Viewray by 843.2% in the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after purchasing an additional 14,789 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Viewray by 5.0% in the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after purchasing an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Viewray in the second quarter worth $159,000. White Pine Capital LLC bought a new stake in Viewray in the second quarter worth $173,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Viewray in the third quarter worth $164,000. Hedge funds and other institutional investors own 50.02% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Viewray Sees Unusually High Options Volume (VRAY)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/12/viewray-sees-unusually-high-options-volume-vray.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.